Board of Directors

Adam Schechter became Chief Executive Officer of Labcorp in 2019 and Chairman of the Board in May 2020. Prior to that, he was named Lead Independent Director after serving as a director of the company since 2013.

Before joining Labcorp, Mr. Schechter held a variety of senior leadership positions at Merck & Co., Inc. He was Executive Vice President and President of Merck’s Global Human Health Division from 2010 to 2018 leading the company’s worldwide pharmaceutical and vaccine businesses. In this role, he was also a member of Merck’s executive committee.

Prior to becoming President of Merck’s Global Human Health Division, Mr. Schechter served as President of Merck’s global pharmaceutical business from 2007 to 2010. His extensive experience at Merck also included global and U.S.-focused leadership roles spanning sales, marketing and managed markets, as well as business and product development.

Mr. Schechter has been a Board Member for DaVita Inc. since 2022, and he serves on the Board for Water.org. He also serves as the American Clinical Laboratory Association (ACLA) Board Vice-Chair, and a member of the Corporate Advisory Council for the National Alliance for Hispanic Health. In 2025, Mr. Schechter joined the Board of Project HOPE, a leading global health and humanitarian organization. Previously, he served on the Boards of the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he led the Policy and Access Committee, the Healthcare Leadership Council and the Merial Animal Health Company.

Mr. Schechter holds a Bachelor of Science degree in biology and an honorary Doctorate of Humane Letters degree from La Salle University in Philadelphia, Pennsylvania.

Victor Bulto has served as a director of the Company since December 1, 2025. Mr. Bulto is President of Novartis US and a member of the Novartis Executive Committee since April 2022. In this role, he leads a bold strategy to reimagine medicine and improve patient care in the world’s largest healthcare market. Mr. Bulto has spearheaded commercial transformation and championed the integration of technology, advanced analytics, real-world evidence and early detection strategies to accelerate access and improve patient outcomes.

With more than two decades at Novartis, he has held senior roles across major therapeutic areas and several geographies, including President of U.S. Pharmaceuticals, Head of U.S. Alcon Pharmaceuticals, and Head of the Neuroscience Franchise for Region Europe.

Mr. Bulto holds a Master’s in Health Economics and Pharmacoeconomics and a Postgraduate Degree in Pharmaceutical Marketing from Universitat Pompeu Fabra. He earned his MBA from ESADE and completed the Advanced Management Program at Harvard Business School. He also holds a Master’s in Chemical Engineering and a Bachelor of Science in Chemistry from Institut Químic de Sarrià in Spain.

Kerrii B. Anderson has served as a director of the Company since May 17, 2006.  Ms. Anderson is the former Chief Executive Officer, President and Chief Financial Officer of Wendy’s International.  Prior to joining Wendy’s in 2000, she was senior vice president and chief financial officer for 14 years for M/I Homes, Inc., a public company that builds single-family homes. 

Ms. Anderson has served as a director of Abercrombie & Fitch Co. since February 2018, The Sherwin-Williams Company since April 2019, and Worthington Industries, Inc. since September 2010.  She was previously a director of the board of Chiquita Brands International from 2009 to 2012, and was chairwoman of the board from 2012 until the company’s acquisition in 2015.   She was also a member of the board of P.F. Chang’s China Bistro from 2009 to 2012.  Ms. Anderson also serves on the boards of the following non-profit entities:  The Columbus Foundation and Elon University Board of Trustees.

Ms. Anderson has received a CERT Certificate in Cyber-Risk Oversight from the Carnegie Mellon University Software Engineering Institute as part of the National Association of Corporate Directors’ Cyber-Risk Oversight Program.

Jeffrey A. Davis has served as a director of the Company since December 1, 2019, and Chairman of the Audit Committee since June 2023. Mr. Davis previously served as the Chief Financial Officer of Dollar Tree, Inc. from October 2022 through March 2025. Prior to his time at Dollar Tree, Inc., Mr. Davis served as Chief Financial Officer of Qurate Retail Group, a leading retailer and media conglomerate comprised of eight retail brands including QVC, HSN and Zulily, from October 2018 through August 2022. Prior to Qurate Retail Group, Mr. Davis served as Chief Financial Officer of J. C. Penney Company Inc., a retail company, from July 2017 until September 2018. Prior to joining J. C. Penney, Mr. Davis served as Chief Financial Officer of Darden Restaurants Inc., a restaurant operator, from July 2015 until March 2016 and Chief Financial Officer of the Walmart U.S. segment of Walmart Inc. from January 2014 to May 2015, and in various other positions of increasing responsibility at Walmart U.S. from 2006 to 2013.  Mr. Davis previously served on the Board and Audit Committee of Massmart Holdings Limited (MSM: Johannesburg Stock Exchange), a South African retailer, from 2011 to 2014, on the Board of Visitors for the Wake Forest University School of Business from 2015 to 2017, and on the Board of Visitors for the Joseph M. Katz Graduate School of Business at the University of Pittsburgh from 2010 to 2016.  Mr. Davis’ experience also includes nine years in senior executive roles at Lakeland Tours LLC and McKesson Corporation. 

Mr. Davis holds a bachelor’s degree in accounting from the Pennsylvania State University and a master’s degree in business administration from the Joseph M. Katz Graduate School of Business at the University of Pittsburgh. Mr. Davis is a certified public accountant (inactive) and has received a CERT Certificate in Cyber-Risk Oversight from the Carnegie Mellon University Software Engineering Institute as part of the National Association of Corporate Directors’ Cyber-Risk Oversight Program.
 

Kirsten M. Kliphouse has served as a director of the Company since October 12, 2022. Ms. Kliphouse previously served as the President of Google Cloud Americas, a public cloud vendor that offers a suite of computing services, a position she held from March 2022 to June 2023, where she was responsible for leading and growing the sales, go-to-market, customer engagement, channel, and services organizations. At Google Cloud, she also served as the Global Chair of the Aspiring Leadership Academy and Women@Google Cloud. Prior to her position as President, Ms. Kliphouse served as President of the North American division of Google Cloud from June 2019 to March 2022.

Prior to Google Cloud, Ms. Kliphouse was Senior Vice President at Red Hat, Inc., a subsidiary of International Business Machines Corporation, Chief Executive Officer of Yardarm Technologies, a hardware and software solutions company, and founder and Chief Executive Officer of Scaling Ventures, a technology investment and advisory firm. Prior to her position at Yardarm, Ms. Kliphouse spent more than 25 years at Microsoft, Inc., where she was part of the executive leadership team and held numerous executive positions in Enterprise Sales, Original Equipment Manufacturers (OEM), Partner and Channels, and as Corporate Vice President of Customer Support, Success and Professional Services, during which she led more than 10,000-employees globally. Ms. Kliphouse is a recipient of the Founders Award for her superior leadership and contributions to the business.

Ms. Kliphouse has served as a director of Global Payments, Inc. since October 2023.  Ms. Kliphouse previously served as a director of Dun & Bradstreet Holdings, Inc. from July 2023 to August 2025 and also served as a director of Vimeo, Inc. from June 2025 until the Company’s acquisition in November 2025.

Ms. Kliphouse holds a degree in Computer Information Sciences and Business from Muhlenberg College.

Garheng Kong has served as a director of the Company since December 2013, Lead Independent Director since June 2023, and Vice Chairman of the Board since December 2025. Dr. Kong also serves as the Chair of the Nominating and Corporate Governance Committee for the Company. Dr. Kong is the managing partner of HealthQuest Capital, a healthcare-focused investment firm, a role he has held since he founded HealthQuest Capital in 2012. He was previously a general partner at Sofinnova Investments, a healthcare investment firm, a position he held from 2010 to 2013. Before joining Sofinnova, Dr. Kong was a general partner from 2000 to 2010 at Intersouth Partners, a venture capital firm, where he was a founding investor or board member for various life science ventures, several of which were acquired by large pharmaceutical companies. Prior to his investing career, Dr. Kong was employed by GlaxoSmithKline, McKinsey & Company, and TherOx.

Dr. Kong serves on the board of directors of Xeris Biopharma Holdings, Inc., a biopharma company, since 2015; Smith & Nephew, a medical device company, since 2025; and IKS Health, a care enablement platform company, since 2025.  Dr. Kong previously served on the board of directors of Alimera Sciences, Inc., a pharmaceutical company that specializes in the commercialization and development of ophthalmic pharmaceuticals, from October 2012 to May 2023; Histogenics Corporation, a biotechnology company, from July 2012 until February 2019; Avedro, Inc., a commercial-stage ophthalmic medical technology company, from April 2017 until November 2019; Melinta Therapeutics, Inc., a pharmaceutical company formerly known as Cempra Pharmaceuticals, from September 2006 until June 2019; and Venus Concept, a medical technology company, from July 2017 to December 2024. Dr. Kong has also served on the boards of Duke University, Duke University Health System, Be The Match, Dell Children’s Foundation, University of Texas President’s Commercial Advisory Board, and the Austin Healthcare Council.

Dr. Kong received undergraduate degrees in both Chemical Engineering and Biological Sciences from Stanford University, and earned an M.D., Ph.D. and MBA from Duke University.

Peter M. Neupert has served as a director of the Company since January 1, 2013 and previously served as the Board’s lead independent director from July 2019 until June 2023. Mr. Neupert was an Operating Partner at Health Evolution Partners, a health only, middle market private equity firm, from January 2012 until June 2015. Prior to that, Mr. Neupert served as Corporate Vice President of the Microsoft Health Solutions Group from its formation in 2005 to January 2012. Mr. Neupert served on the President George W. Bush’s Information Technology Advisory Committee (PITAC), co-chairing the Health Information Technology Subcommittee and helping to drive the “Revolutionizing Health Care Through Information Technology” report, published in June 2004. Mr. Neupert served as the founding President and Chief Executive Officer of drugstore.com from 1998 to 2001 and as Chairman of the board of directors through September 2004.

Mr. Neupert has served as a director of Fortrea Holdings, Inc. since it became publicly traded in June 2023. Mr. Neupert has served as a director of Adaptive Biotechnologies Corporation since December 2013 and currently serves as the Lead Independent Director. He served on the Board of Directors of Quality Systems, Inc., now known as NextGen Healthcare, Inc., from August 2013 to January 2014. He previously served as a trustee for the Fred Hutchinson Cancer Research Center and was an active member of the Institute of Medicine’s Roundtable on Value & Science-Driven Healthcare from 2007 to 2011. Mr. Neupert is an audit committee financial expert as a result of his experience, including his experience as CEO and Chairman of drugstore.com.

Richelle Parham has served as a director of the Company since February 8, 2016 and Chairperson of the Compensation and Human Capital Committee since June 2023. Ms. Parham previously served as President of Global eCommerce and Business Development for Universal Music Group, a music-based entertainment company, a position she has held from June 2021 to June 2025. In October 2019, Ms. Parham became a Managing Director of WestRiver Group, which provides integrated capital solutions to the global innovation economy with investments focused on technology, life sciences, energy, and experiential sectors. She previously served as a General Partner at Camden Partners, a private equity firm, from October 2016 to October 2019. Prior to Camden Partners, Ms. Parham served as Chief Marketing Officer of eBay from November 2010 to March 2015. Ms. Parham was responsible, globally, for developing eBay brand strategy and brand marketing to reach 108+ million active eBay users. Prior to joining eBay, Ms. Parham served as head of Global Marketing Innovation and Initiatives and head of Global Marketing Services at Visa Inc. from 2008 to 2010. Her experience also includes 13 years at Digitas, Inc., a leading marketing agency, where she held a variety of senior leadership roles, including senior vice president and general manager of the agency’s Chicago office.

Ms. Parham has served as a Director of Best Buy Co., Inc. since March 2018. She served on the board of directors for e.l.f. Beauty, Inc. from March 2018 to June 2022 and Scripps Network Interactive Inc. from 2012 until March 2018, when Scripps Network Interactive was acquired by Discovery Communications.

Ms. Parham holds double Bachelor of Science degrees in business administration and design arts from Drexel University. She became a member of the Drexel University board of trustees in 2014.

Paul B. Rothman has served as a director of the Company since June 6, 2023 and as Chairman of the Quality and Compliance Committee since June 2024. Dr. Rothman, a rheumatologist and molecular immunologist, was previously the Dean of the Medical Faculty for Johns Hopkins University School of Medicine and CEO of Johns Hopkins Medicine, during which time he oversaw both the Johns Hopkins Health System and the School of Medicine. Prior to serving at Johns Hopkins, Dr. Rothman held various leadership positions at Columbia University and the University of Iowa.

Dr. Rothman currently serves on the board of directors of Merck and Co. and the King Faisal Specialist Hospital and Research Center in Saudi Arabia. In addition, he consults for several investment firms including RA Capital, Mingxin Capital Growth Fund and ANV Management.

Dr. Rothman holds a Bachelor of Science degree in biology from the Massachusetts Institute of Technology and an M.D. from Yale University, and is a member of the National Academy of Medicine, the American Academy of Arts and Sciences, the American Association for the Advancement of Sciences, the American Society for Clinical Investigation, and the Association of American Physicians.

John H. Sampson has served as a director of the Company since February 9, 2026. Dr. Sampson is the Richard D. Krugman Endowed Chair, Vice Chancellor for Health Affairs, Dean of the University of Colorado Anschutz School of Medicine, and President of CU Medicine. Prior to serving at the University of Colorado, he was Senior Vice Present in the Duke University Health System and led the Duke Health Integrated Practice.

As a nationally recognized neurosurgeon, physician-scientist and academic leader, Dr. Sampson brings extensive experience spanning clinical care, biomedical research, medical education and large-scale health system leadership. He is a practicing neurosurgeon and has authored nearly 300 peer-reviewed publications, with a long track record of research focused on advancing new therapies for neurologic disease.

Dr. Sampson was born in Canada and holds a Bachelor of Science degree and an MD from the University of Manitoba. He is a member of the National Academy of Medicine, American Society for Clinical Investigation, and the Association of American Physicians.

Kathryn E. Wengel has served as a director of the Company since March 25, 2021. Ms. Wengel has served as the Executive Vice President, Chief Technical Operations & Risk Officer of Johnson & Johnson, a leading healthcare company, since January 2023, and as an Executive Committee member and an Executive Officer of Johnson & Johnson since July 2018. Ms. Wengel has significant healthcare, operations, and global business expertise, with more than three decades of experience in leadership positions at Johnson & Johnson in the United States and various locations globally, including as its Worldwide VP and then Executive Vice President, Chief Global Supply Chain Officer from March 2014 through December 2022, and its first Chief Quality Officer from April 2010 until March 2014.

Ms. Wengel has served as the Chair of the Board of Directors at the National Association of Manufacturers in the U.S. and is a member of their Executive Committee, as well as a member of the Board of GS1 Global, a nonprofit that develops and maintains global supply chain standards.

Ms. Wengel holds a Bachelor of Science in Engineering degree in civil engineering and operations research from Princeton University.